Iboga Treatment

/Iboga Treatment
Iboga Treatment 2018-01-29T08:24:12+00:00

Iboga Treatment

Our establishment is situated in the picturesque location of Vredehoek/Devils Peak in the city bowl of Cape Town; beneath the foot of our famous land mark Table Mountain. Cape Town has been noted as a top destination marked for travel and tourism (and medical tourism) and offers a unique and unforgettable experience in this respect. Many patients consider this as an advantage of the treatment taking place in such a unique locale. View some pictures of our center and patient accommodation and learn more about our staff.

We offer treatment along with 48Hrs of constant nurse supervision in an idyllic environment suited to the treatment process. The patient and their vitals are monitored for the duration of stay; and we will go to great lengths to assure the patients comfort and privacy throughout the course of their stay. Any special requirements such as diet and so on will be considered.

Let us know before hand and we will do what we can to accommodate you.

We now have a second; and now our primary treatment centre in Cape Town.

The treatment centre is up market; private and in an inviting renovated hotel; a piece of history. I will be writing more shortly on the subject…watch this space and have a look at the photos!

Treatment process

We treat one patient at a time to ensure the maximum amount of attention needed to address the condition and to enable the patient to achieve their goal whatever that may be; as we believe every patient requires individual attention and unique approach to achieve a successful long term outcome.

Ibogaine allows the brain to enter a waking REM state where memories; life experiences; and issues of trauma are processed in a subjective manner. In the majority of cases I have worked on personally or studied: At the root of any given destructive behavioural pattern or coping mechanism was a repressed trauma; which ibogaine allowed access to while resetting the reward pathway and preventing withdrawal symptoms by 95% or more. Ibogaine negates the craving associated with with opiates like Heroin and Oxycontin; Cocaine; Methamphetamine (TIK); Alcohol and Nicotine.

Ibogaine has been found to activate a growth factor; Glial cell line-derived Neurotrophic Factor; that regenerates dopamine neurons suppressed by excessive drug use; and also back-signals the cell nuclei to express more GDNF by effectively creating a loop.

A treatment is looked at over a period of up to six months where we can administer low doses of iboga root bark or the precipitated alkaloids to help the patient with craving and mood swings after the initial treatment or re-set which is common after any type of detox procedure. This stage of the treatment can be done on an out patient basis with a minimal amount of supervision or contact between the patient and provider; to ensure long term success and also to buy the patient more time to make life style changes.
Another reason for looking at treatment over an extended period of time is because we can not guarantee the psycho-spiritual depth of the experience from a single treatment.
We found that there were considerable differences even when the same dose and same batch was used on the patient at a different time; the depth of the experience varied (or can vary) and at times quite considerably with regard to psycho therapy and personal awareness.

Ibogaine is metabolised and stored in the liver as Nor-Ibogaine which leaves the patient with no or little desire to use drugs and an anti-depressant effect causing the patient to feel positive after treatment. This effect can last several months but may be extended by the use of low doses of Iboga root bark or extracts which are commonly referred to as boosters.

More on GDNF and Ibogaine

One reason Ibogaine is so interesting is that it increases levels of glial cell line-derived neurotrophic factor (GDNF) in the brain (He & Ron 2006), and this in turn appears to have neuroprotective properties that promote the survival of both dopaminergic and motor neurons (Bermingham et al. 2004; He and Ron 2006), which may be one of the reasons for the prolonged afterglow often experienced following treatment with the drug. GDNF has also been identified as having anti-addictive properties (Ron & Janak 2005; Carnicella & Ron 2008).  Furthermore, GDNF can cause sprouting of dopaminergic fibers and clinical improvement in experimental animal models of Parkinson’s disease, as well as a similar sprouting of dopaminergic fibers in humans with the disease, with the resultant clinical improvement in symptoms (Love et al. 2005). This may be one of the reasons for Ibogaine’s effectiveness in treating drug addicts with impaired receptor function, but this drug may also be a considerable ally to those with degenerative neurological diseases.

Both Parkinson’s disease and Motor neuron disease are chronic disorders with no known cure, and require management with drugs that can have considerable side effects, causing a very poor quality of life for terminal stage sufferers of these diseases. By contrast, a low dose regime of Ibogaine or Iboga alkaloid extract would be of low toxicity and free of serious side effects.

GDNF has been shown to have potent neurotrophic factor in both rodent and primate models of Parkinson’s disease (Gill et al. 2003). Direct brain infusion of GDNF into the brains of five Parkinson sufferers resulted in a 39% improvement in the off-medication motor sub-score of the Unite Parkinson’s Disease Rating Scale (UPDRS) and a 61% improvement in the activities of daily living sub score (Gill et al. 2003). Positron emission tomography (PET) scans of dopamine uptake showed a significant 28% increase in putamen dopamine storage after 18 months, indicating a direct effect of GDNF on dopamine function. Furthermore, after one year, no serious clinical side effects were observed (Gill et al.2003). The use of Iboga alkaloid extract or Ibogaine would provide a longer term and much less invasive method of GDNF administration than direct brain infusion. Thus, further research on Ibogaine and GDNF is certainly warranted.

Regarding motor neuron disease, the little research that has occurred in this area, such as gene transfer of neurotrophic factors, suggests new prospects in the treatment of motor neuron disease (Haase et al. 1997). Again, Ibogaine therapy may offer a straightforward, non-invasive, cheap, low-toxicity method of treatment for sufferers of this disease.

Thus based on this previous research, it seems clear to me that further research with Ibogaine, GDNF expression and neurodegenerative diseases is certainly warranted, despite the financial and political hurdles of working with Ibogaine, a largely scheduled yet natural alkaloid extract from the root bark of the West African shrub Iboga (Tabernanthe iboga). The drug is of little financial interest to pharmaceutical companies, and quite inaccurately deemed to be of “no medical value”. Legal red tape is less restrictive for Ibogaine here in the UK than it is in many other parts of the world.

Ibogaine has been used in treating or facilitating the following:
  • Opiate dependence
  • Cocaine dependance
  • Methamphetamine (TIK) addiction
  • Alcoholism-Binge drinking
  • Nicotine addiction
  • Depression
  • Eating disorders
  • Repressed trauma
  • Self awareness
  • Spiritual upliftment and development

Once the patient has made contact and adhered to the screening process; which includes and ECG (electrocardiogram or heart stress test) to test for a prolonged Q-T interval as well as a blood-liver panel to ensure a clean bill of health. A 50% deposit is required in order to set a date for treatment. We work on a first come first served basis but in general a patient can expect treatment within a week to ten days after the patient is deemed suitable for treatment and the deposit has been received.

We will not tolerate any type of coercion even though treatment saturated patients become treatable after the ibogaine experience. We want the patient to be able to take on the responsibility of their own treatment or recovery in time; with the tools and support we make available or suggest to them. Parents or friends are welcome to make inquiries but it is crucial to long term success to have the full commitment of the patient as well as the friends and family in addressing these issues.

We offer support at any given time but encourage the family and or friends to take an active role in the recovery phase as a support base for the patient; acceptance; tolerance and understanding are key not judgement and punishment.

As part of the screening process the patient will be issued a questionnaire and a pre-treatment supplement. The questionnaire will provide us with a medical; psychological and social history which should be filled out with as much detail as possible. The Pre-Treatment supplement will provide you with information on how to prepare for the experience; what you should or should not do (like eating grape fruit; which is a no-no and interferes in the metabolisation of ibogaine)
What to bring and what to expect during your stay as well as information related to after care and dietary supplements that are beneficial to the process.

Once again if there are any questions that have not yet been addressed feel free to email or call.

Simon Loxton
NHP/D.Emed